Detailed Chemical Abundances of Globular Clusters in Local Group Dwarf Galaxies

We present detailed chemical abundances of Fe, Ca and Ba for 17 globular clusters (GCs) in 5 Local Group dwarf galaxies: NGC 205, NGC 6822, WLM, the SMC and LMC. These abundances are part of a larger sample of over 20 individual elements measured in GCs in these galaxies using a new analysis method for high resolution, integrated light spectra. Our analysis also provides age and stellar population constraints. The existence of GCs in dwarf galaxies with a range of ages implies that there were episodes of rapid star formation throughout the history of these galaxies; the abundance ratios of these clusters suggest that the duration of these burst varied considerably from galaxy to galaxy. We find evolution of Fe, Ca, and Ba with age in the LMC, SMC, and NGC 6822 that is consistent with extended, lower-efficiency SF between bursts, with an increasing contribution of low-metallicity AGB ejecta at late times. Our sample of GCs in NGC 205 and WLM are predominantly old and metal-poor with high [Ca/Fe] ratios, implying that the early history of these galaxies was marked by consistently high SF rates.Comment: 2 pages, To appear in the proceedings of the conference "A Universe of Dwarf Galaxies" (Lyon, June 14-18, 2010

Galectin-3 is associated with stage B metabolic heart disease and pulmonary hypertension in young obese patients

Background Obesity is a precursor to heart failure with preserved ejection fraction. Biomarkers that identify preclinical metabolic heart disease ( MHD ) in young obese patients would help identify high-risk individuals for heart failure prevention strategies. We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease. Methods and Results Asymptomatic obese patients (n=250) and non-obese controls (n=21) underwent echocardiographic cardiac phenotyping. Obese patients were classified as MHD positive ( MHD - POS ; n=94) if they had abnormal diastolic function or left ventricular hypertrophy and had estimated pulmonary artery systolic pressure ≥35 mm Hg. Obese patients without such abnormalities were classified as MHD negative (MHD-NEG; n=52). Serum biomarkers timed with echocardiography. MHD - POS and MHD-NEG individuals were similarly obese, but MHD - POS patients were older, with more diabetes mellitus and metabolic syndrome. Right ventricular coupling was worse in MHD - POS patients ( P<0.001). GAL 3 levels were higher in MHD - POS versus MHD -NEG patients (7.7±2.3 versus 6.3±1.9 ng/mL, respectively; P<0.001). Both GAL 3 and FSTL 3 levels correlated with diastolic dysfunction and increased pulmonary artery systolic pressure but not with left ventricular mass. In multivariate models including all 3 biomarkers, only GAL 3 remained associated with MHD (odds ratio: 1.30; 95% CI , 1.01-1.68; P=0.04). Conclusions In young obese individuals without known cardiovascular disease, GAL 3 is associated with the presence of preclinical MHD . GAL 3 may be useful in screening for preclinical MHD and identifying individuals with increased risk of progression to obesity-related heart failure with preserved ejection fraction.Deepa M. Gopal, Nir Ayalon, Yi, Chih Wang, Deborah Siwik, Aaron Sverdlov, Courtney Donohue ... et al